$MARK Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital Roth Capital analyst Darren Aftahi notes that privately-held Sharecare, which he estimates Remark Holdings (MARK) owns about 4.5% of, recently announced Quest Diagnostics (DGX) as its preferred laboratory partner, with Quest also making a strategic investment in the company. The analyst believes this could set the stage for a potential IPO going forward. Based on his current analysis, Aftahi thinks Remark's stake is worth about $150M-$175M, implying about $3.65-$4.31/share, multiples of its current $43M value. A liquidity event in Sharecare would help to much better capitalize Remark's AI business, he contends. The analyst reiterates a Buy rating and $7.50 price target on Remark's shares.